Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Isentress (raltegravir) label update

On February 18, 2015, FDA approved changes to the Isentress (raltegravir) label to include updated information regarding the coadministration of raltegravir and aluminum and/or magnesium containing antacid.

Published
19 February 2015
From
FDA
Biologist's Work on 'Viral Reservoirs' May Have Impact on AIDS/HIV

A drug used to treat patients with multiple sclerosis and Crohn’s disease has confirmed how “viral reservoirs” form in patients living with HIV and AIDS and also proven effective in animal trials at blocking the pathways to those reservoirs in the brain and gut, according to new research conducted by Professor of Biology Ken Williams and colleagues from other universities.

Published
19 February 2015
From
Boston College Chronicle
Experimental AIDS Drug Stirs Talk Of Vaccine 'Alternative'

For more than three decades, scientists have tried unsuccessfully to develop an effective vaccine for HIV, the virus that causes AIDS. But now researchers say they have created an experimental drug that may function as a sort of "alternative" vaccine for the virus. The experimental drug, a protein known as eCD4-IG, blocks infection by keeping the virus from binding to the immune cells that are the virus's target. In tests on monkeys, the drug "candidate" proved to be extremely effective at blocking infection--even with the most virulent strains of HIV and its simian counterpart, SIV.

Published
19 February 2015
From
Huffington Post
Researchers may have caught HIV becoming more virulent

A study from Cuba has generated wide media interest because researchers have identified a particular variety of the virus which is associated with rapid post-diagnosis falls in

Published
19 February 2015
By
Gus Cairns
The Search for a Permanent Alternative to HIV Drugs

Researchers Carefully Tailor a Study to Find Patients to Test Going Off Antiretroviral Medication

Published
16 February 2015
From
Wall Street Journal
Health News Review analysis of Reuters' coverage of new hepatitis C drugs

We wish that more stories would bring some skeptical thinking to their coverage of expensive new hepatitis C treatments. The emphasis on short-term effects obscures the lack of long-term data about benefits.

Published
13 February 2015
From
Health News Review
Next-Generation HIV and Hep C Treatment Plans Ahead at CROI

New research on the treatment and prevention of HIV/AIDS and hepatitis C will dominate the Conference on Retroviruses and Opportunistic Infections (CROI) 2015, which this year adds a special session on Ebola.

Published
13 February 2015
From
Medscape (free registration required)
Dutrebis, New HIV Drug, Approved by FDA, but Not Commercially Available

The new combination contains 150 mg of lamivudine (3TC, Epivir) and 300 mg of raltegravir (Isentress). Despite the FDA approval, the drug manufacturer, Merck Pharmaceuticals, announced that they would not be making Dutrebis commercially available in the U.S. at this time.

Published
11 February 2015
From
The Body Pro
HIV Organizations Urge Continuation of D:A:D Study

D:A:D follows 50,000 HIV-positive people, looking at drug safety and side effects over time. Results from D:A:D have changed HIV treatment guidelines, and how HIV-positive people are treated by their health care providers. We urge pharmaceutical companies to continue funding this vital study.

Published
11 February 2015
From
Treatment Action Group
A more personalised approach to hepatitis C treatment may improve adherence and completion rates

People receiving treatment for hepatitis C value clinicians who give information and clinical feedback that is personalised to their individual needs and lifestyle, and cite this as

Published
11 February 2015
By
Roger Pebody

Filter by country